2026-07-11T18:24:49Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/119102026-07-10T00:05:17Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

Apellaniz-Ruiz, Maria Barrachina, Jordi Castro-Sanchez, Paula Comes-Raga, Ana García-González, Xandra Gil-Rodriguez, Almudena Lopez-Lopez, Elixabet Maroñas, Olalla Morón, Rocío Muriel, Javier Olivera, Gladys G. Riera, Pau Saiz-Rodríguez, Miriam Salvador-Martín, Sara Sans-Pola, Carla Tejera-Pérez, Hugo Velasco-Ruiz, Alejandro Verde, Zoraida Wang, Daniel Rodríguez-Vicente, Ana E. Nunez-Torres, Rocio 2026-07-09T11:31:53Z 2026-07-09T11:31:53Z 2025-11 https://hdl.handle.net/10259/11910 10.1515/dmpt-2024-0042 2363-8915 Introduction: Pharmacogenetics (PGx) has the potential to improve patient care, allowing to transform medical interventions by providing personalized therapeutic strategies. Scientific evidence supports the use of PGx in clinical practice and international organizations are developing clinical guidelines to facilitate the utilization of PGx testing. However, clinical implementation of PGx is limited and unequal worldwide. Content: This review summarizes regional and national Spanish initiatives to implement PGx in the clinical practice. Summary and Outlook: Diverse strategies to implement PGx in healthcare are applied across countries or even in the different regions of a specific country. Such was the case of Spain, a European country with 17 Autonomous Regions and two Autonomous Cities, each onewith capacity tomanage their own healthcare systems. Nevertheless, during the past years, many initiatives and strategies have been launched in Spain to develop different aspects of PGx. Importantly, the National Healthcare System has approved a PGx testing catalogue. This review highlights the crucial work and efforts of scientific societies (like the Spanish Society of Pharmacogenetics and Pharmacogenomics), of experts in PGx, of healthcare providers and of governmental parties in the implementation of PGx to personalize patient therapy, focused in Spain. MA-R received a Postdoctoral Junior Leader–INCOMING Fellowship from “la Caixa” Foundation (ID: 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska Curie grant agreement No. 847648 (fellowship code: LCF/BQ/PI21/11830009). PR has a Juan Rodés fellowship funded by the Instituto de Salud Carlos III (code: JR20/00008). AV-R received a Doctoral Grant FPU by the Spanish Ministry of Science and Innovation (FPU17-04877). The rest of the authors declare no funding. eng Drug Metabolism and Personalized Therapy. 2024, V.39, n. 4, p. 183-199 https://doi.org/10.1515/dmpt-2024-0042 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Clinical implementation Personalized medicine Pharmacogenetics Pharmacogenomics Spanish national healthcare system Medicina personalizada Farmacogenómica Precision medicine Pharmacogenomics Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Drug Metabolism and Personalized Therapy 39 4 183 199